T. Rowe Price Investment Management
REGN icon

T. Rowe Price Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

T. Rowe Price Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-267
Closed -$207K – 790
2026
Q1 		$207K Buy
+267
New +$204K ﹤0.01% 643
2025
Q4 		– Sell
-435
Closed -$245K – 948
2025
Q3 		$245K Buy
435
+147
+51% +$83.1K ﹤0.01% 657
2025
Q2 		$152K Buy
+288
New +$161K ﹤0.01% 659

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

T. Rowe Price Investment Management's REGN Position: Q2 2026 in Review

T. Rowe Price Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 267 shares — an estimated $207K sold.

T. Rowe Price Investment Management first reported a position in REGN in Q2 2025 and held it in 3 quarters. The position peaked at $245K in Q3 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • T. Rowe Price Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 267 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • T. Rowe Price Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Investment Management's Regeneron Pharmaceuticals position peaked at $245K in Q3 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.